Oral changes in patients undergoing chemotherapy for breast cancer

Acharya, Shruthi; Pai, Keerthilatha Murlidhar; Bhat, Smitha; Ballal, Mamatha; Bejadi, Vadhiraj M

doi:10.4103/ijdr.ijdr_379_16

Cited by 27 publications

(25 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the predictive value of this method is not well established, a fact demonstrated in the 2018 study in which 70% of patients complaining of previous dry mouth had normal salivary flow (21) . On the other hand, in a study of Indian women diagnosed early with breast cancer, there was an absence of xerostomia before chemotherapy, but this condition appeared during treatment and persisted even after 12 weeks (14) .…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Prevalence of xerostomia in women during breast cancer chemotherapy

et al. 2020

View full text Add to dashboard Cite

Objective: To identify the prevalence of xerostomia in women undergoing chemotherapy for breast cancer. Method: Prospective cohort with 27 women who underwent up to 16 sessions of intravenous chemotherapy. Data collection was performed at the outpatient clinic of a university hospital in the city of São Paulo, where two forms were applied before the start of treatment and the Xerostomia Inventory before and after each chemotherapy session. Results: Complaints of dry mouth were present in 48.1% of women before chemotherapy, and they were approximately 28 times more likely to develop dry mouth during treatment. It was observed that the use of antiemetics contributed to the occurrence of xerostomia, and the anti-ulcerous were presented as a protective factor. Conclusion: The study identified both a high prevalence of xerostomia regardless of the chemotherapy used and the need to create protocols to improve the quality of life of these patients.

show abstract

Section: Discussionmentioning

confidence: 92%

“…Among the studies that address breast cancer, chemotherapy and the presence of xerostomia, we highlight one carried out in India, in 2017, with 52 women, in which xerostomia was evaluated before (0%), during chemotherapy (65.4%) and after treatment (44.2%) (14) .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of xerostomia in women during breast cancer chemotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Oral hyperpigmentation induced by chemotherapeutic and antineoplastic agents was reported in 30 and 125 patients, respectively. The most prevalent agent was imatinib 18,21,22,24,36,46,[48][49][50][51][52][53][54][55]57,62 other agents included capecitabine, 16 cyclophosphamide, 25,40 5-fluorouracil, 43 irinotecan, 26 and hydroxyurea. 11 The risk of oral pigmentation in association with imatinib therapy increased as the duration of intake increased (an average of 7 years) and occurred most commonly in the hard palate.…”

Section: Dovepressmentioning

confidence: 99%

<p>Medication-Induced Oral Hyperpigmentation: A Systematic Review</p>

Binmadi¹,

Bawazir²,

Alhindi³

et al. 2020

PPA

View full text Add to dashboard Cite

Background: Medication-induced oral hyperpigmentation is an oral condition that impacts patients' quality of life and has been linked to many systemic therapeutic agents. The exact pathogenesis of tissue pigmentation varies greatly and is not completely known. This systematic review aimed to present data on the causal association between medications and the development of oral/mucosal pigmentation as an adverse drug reaction. Methods: A systematic review and analysis of literature were conducted using the following databases: PubMed, Science Direct, ProQuest, Web of Science, and Scopus. The systematic review included original articles written in English and published between January 1982 and June 2020. Following the PRISMA statement, eligible articles were systematically reviewed, and data were extracted from eligible studies and analyzed. Results: A total of 235 articles were identified, of which 57 met the inclusion criteria and were included in this review. The mean age of included patients was 46.2±16.38 years (range: 10-90 years) with a male to female ratio of 1:1.45. Oral mucosal hyperpigmentation was reported following the use of several classes of medications such as antiviral (eg, zidovudine), antibiotic (eg, minocycline), antimalarial (eg, chloroquine), anti-fungal (eg, ketoconazole), antileprotic (eg, clofazimine), antihypertensive (eg, amlodipine), chemotherapeutic, and antineoplastic drugs. The risk of developing oral pigmentation was significantly higher with antimalarial medications, antibiotics, antineoplastic and chemotherapeutic agents. Medication-induced oral hyperpigmentation was most frequent among women and in the hard palate. Conclusion: Future research is warranted to better understand the pathogenesis and risk factors for medication-induced oral hyperpigmentation in order to reassure patients during prescription and management.

show abstract

“…17,18 U pacjentów w trakcie chemioterapii raka płuc, jajnika, prostaty oraz szpiczaka mnogiego stosuję się substancje antyresorpcyjne z grupy bisfosfonianów, w celu ograniczenia ubytków tkanki kostnej. 19 Preparaty te wpływają na apoptozę osteocytów, wzrost aktywności osteotwórczej i uwapnienie kości, przez co utrudniony jest rozsiew komórek nowotworowych do szpiku kostnego. Łagodzą również bóle kostne w przebiegu szpiczaka mnogiego.…”

Section: Wpływ Leczenia Onkologicznego Na Stan Podłoża Kostnegounclassified

“…38 Bardzo często w wyniku leczenia onkologicznego dochodzi do zaburzenia funkcji gruczołów ślinowych. 19 Wydzielana jest skąpa ilość śliny, która jest gęsta i lepka, ma mniejszą zdolność buforową oraz właściwości obronne. 39 Ograniczona ilość laktoferyny, laktoperoksydazy i immunoglobulin sprzyja próchnicy oraz infekcjom w jamie ustnej.…”

Section: Uzębienie Resztkowe I Gruczoły śLinoweunclassified

Changes in the prosthetic base in oncological patients – review of literature

Łazarz-Półkoszek¹,

Loster²

2020

Prosthodontics

View full text Add to dashboard Cite

Wprowadzenie. Terapia przeciwnowotworowa obejmuje postępowanie chirurgiczne, radioterapię i chemioterapię. Zabieg chirurgiczny wiąże się z naruszeniem ciągłości tkanek, ubytkami poresekcyjnymi, okresem gojenia oraz rehabilitacją pooperacyjną. Działanie jatrogenne chemioterapii i promieniowania skutkuje powikłaniami ogólnoustrojowymi oraz zmianami w jamie ustnej, które wymagają odpowiedniego postępowania stomatologicznego. Cel pracy. Celem pracy był przegląd piśmiennictwa dotyczącego oceny wpływu terapii przeciwnowotworowej na stan podłoża protetycznego oraz planowane leczenie.

show abstract

Oral changes in patients undergoing chemotherapy for breast cancer

Abstract: There was a discernible change in oral mucosal, salivary, and candidal status during the course of the study.

Cited by 27 publications

References 2 publications

Prevalence of xerostomia in women during breast cancer chemotherapy

Prevalence of xerostomia in women during breast cancer chemotherapy

<p>Medication-Induced Oral Hyperpigmentation: A Systematic Review</p>

Changes in the prosthetic base in oncological patients – review of literature

Contact Info

Product

Resources

About